Global Urinary Tract Infection Therapeutics Market - 2020-2027
Urinary Tract Infection (UTI) occurs when bacteria penetrate the urethra and infects the urinary bladder, instigating severe health issues. It is considered a common health problem in females compared to males. Antibiotics are typically the first line of treatment recommended by doctors for the treatment of urinary tract infections. Excessive and uncontrolled passing of urine at night and the painful and increased frequency of urination are the widespread symptoms related to UTI.
The global urinary tract infection therapeutics market size was worth US$ XX billion in 2019 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).
Certain factors that are leading the market growth include the increasing prevalence of diabetes and kidney stones, the introduction of emerging technologies for the diagnosis of urinary tract infection, and the launch of combination drugs.
Increasing Prevalence of Diabetes and Kidney Stones
The diabetic population has observed an exponential rise across the globe. Changes in lifestyle, sedentary work, unhealthy eating habits, family history, and reduced physical workouts have led to an increase in obesity, which is the major cause of type 2 diabetes in adults. Moreover, according to the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), kidney stones are common, and their incidence is rising significantly. Nearly 11.0% of men and 6.0% of women in the US have kidney stones at least once in their lifetime. Considering the rising prevalence of kidney stones and Mellitus globally, the demand for urinary tract infection therapeutics is expected to increase during the forecast period.
Introduction of emerging technologies for diagnosis
Continuous development of advanced technologies for the accurate and timely diagnosis of urinary tract infection is expected to increase the number of diagnosed cases of urinary tract infection, which in turn, will enhance the treatment of patients. Emerging technologies, including biosensors and microfluidics, are expected to enhance the diagnosis of disease, which in turn will boost the urinary tract infection treatment market during the forecast period.
COVID-19 Impact Analysis
A considerable decline in the urinary tract infection therapeutics market value was estimated in 2020 due to the outbreak of the COVID-19 pandemic across the globe. During the COVID-19 outbreak, the lockdown was implemented across the majority of the nations globally, which in turn declined the consumption of unhealthy foods, leading to the decline in the number of cases related to infection, including urinary tract infection. Moreover, the hospital visits were considerably declined during the COVID-19 outbreak, owing to which the urinary tract infection diagnosis declined globally, leading to the downfall of the urinary tract infection therapeutics market in 2020.
Based on the drug type, the urinary tract infection therapeutics market has been classified into Penicillin and combinations, quinolones, cephalosporin, azoles and amphotericin B, nitrofurans, and others.
Quinolones lead the market throughout the forecast period
Quinolones segment led the overall market with a share in 2019. A majority of physicians recommend quinolones for the treatment of complicated urinary tract infections. Cephalosporin is considered the second-most common drug recommended for the treatment of complicated urinary tract infections. The prevalence of complicated urinary tract infection is set to escalate during the forecast period, mainly owing to the increasing bacterial resistance in urinary tract infection cases and the rise in recurrence rate for urinary tract infection.
Based on the indication, the urinary tract infection therapeutics market has been classified into complicated urinary tract infections, uncomplicated urinary tract infections, and others.
The complicated urinary tract infection segment dominated the global urinary tract infection therapeutics market in 2019
The complicated urinary tract infection segment accounted for the largest share in the global market in 2019. The prevalence of complicated urinary tract infections is expected to propel at a considerable growth during the forecast period, owing to the excessive use of antibiotics and the rise in drug-resistant bacteria. Comparatively, uncomplicated urinary tract infection does not last longer than complicated urinary tract infection; therefore, the treatment procedure for complicated urinary tract infection contributes relatively more to the growth of the urinary tract infection therapeutics market across the globe.
Based on geography, the study analyzes the urinary tract infection therapeutics market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.
North America leads the global market throughout the forecast period
North America dominated the global urinary tract infection therapeutics market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American urinary tract infection therapeutics market in 2019. The major factors leading to the growth of the market in the region include the well-developed healthcare infrastructure and the high awareness amongst the public regarding the treatment of urinary tract infection. Moreover, the presence of some of the key market players, such as Becton, Dickinson and Company, and Johnson & Johnson Services Inc., is further augmenting the growth of the market in the region.
Moreover, Asia Pacific is expected to project the fastest growth rate in the urinary tract infection therapeutics market during the forecast period. China dominates the market, whereas India is estimated to exhibit considerable growth in the Asia Pacific urinary tract infection therapeutics market during the forecast period. The expansion of the market players in the emerging economies of the region, such as India, Vietnam, is expected to propel the demand for urinary tract infection therapeutics in the region.
The urinary tract infection therapeutics market is highly competitive, owing to the large presence of urinary tract infection therapeutics brands. The key urinary tract infection therapeutics players include Cipla Ltd., Becton, Dickinson, and Company, Bayer AG, Boehringer Ingelheim GmbH, AstraZeneca Plc, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG, Johnson & Johnson Services Inc. The crucial players are adopting new product launches and expansion strategies for global growth in the urinary tract infection therapeutics market.
Overview: Boehringer Ingelheim GmbH was established in 1885 and is based in Ingelheim am Rhein, Germany. By serving innovative drugs, the company focuses on therapeutic areas, including respiratory diseases, metabolic diseases, cardiovascular diseases, oncology, virological diseases, and others. The company has over 51000 employee base and deals in Human Pharma, Animal health, and Biopharma. The company offers innovative therapies for improving diabetic conditions globally.
Product Portfolio: The company's portfolio comprises a wide range of kitchen and laundry appliances.
The global urinary tract infection therapeutics market report would provide access to an approx. 60 market data tables, 57 figures, and 272 pages.
LIST NOT EXHAUSTIVE